Corinne Haioun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7226639/publications.pdf

Version: 2024-02-01

932766 1372195 1,140 11 10 10 citations h-index g-index papers 11 11 11 1557 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas. Blood, 2016, 128, 1490-1502.	0.6	255
2	Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica, 2017, 102, e148-e151.	1.7	163
3	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. Journal of Clinical Oncology, 2017, 35, 2008-2017.	0.8	155
4	Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood, 2018, 132, 2305-2309.	0.6	124
5	A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (RevlimidÂ $^{\circ}$) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. European Journal of Cancer, 2013, 49, 2869-2876.	1.3	114
6	Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica, 2015, 100, e361-e364.	1.7	98
7	The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 15084-15089.	3.3	96
8	Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica, 2012, 97, 1594-1602.	1.7	76
9	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Advances, 2021, 5, 539-548.	2.5	38
10	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Lancet Haematology,the, 2018, 5, e403-e410.	2.2	21
11	Development of a Questionnaire for the Search for Occupational Causes in Patients with Non-Hodgkin Lymphoma: The RHELYPRO Study. International Journal of Environmental Research and Public Health, 2021, 18, 4008.	1.2	0